Ex­elix­is, Bris­tol-My­ers mount piv­otal study of Cabo/Op­di­vo com­bo for front­line kid­ney can­cer

Just days af­ter re­view­ing a promis­ing start com­bin­ing Bris­tol-My­ers Squibb’s check­point in­hibitor Op­di­vo (nivolum­ab) with Cabome­tyx (cabozan­ti­nib), Ex­elix­is is rolling out a late-stage part­ner­ship …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER